Neoadjuvant immunotherapy driven bladder preservation for muscle invasive bladder cancer

Jiao Hu; Luzhe Yan; Jinhui Liu; Minfeng Chen; Yunbo He; Benyi Fan; Bo Peng; Long Wang; Weibin Hou; Chao Li; Bosen You; Meng Zhang; Wenze Li; Jiaxing Wang; Hongzhou Cai; Shenglin Gao; Yang Liu; Dingshan Deng; Huihuang Li; Guanghui Gong; Jiansheng Tang; Chengyong Wang; Xiaofeng Yang; Liang Wei; Guangzheng Lin; Ruizhe Wang; Xiao Guan; Shiyu Tong; Yangle Li; Wei He; Zhiyong Cai; Peihua Liu; Yu Gan; Yu Cui; Yuanqing Dai; Yi Cai; Zefu Liu; Jiatong Xiao; Zhenyu Nie; Zhenyu Ou; Jinbo Chen; Xi Guo; Xiongbing Zu

doi:10.1002/imt2.70063

iMeta ›› 2025, Vol. 4 ›› Issue (4) :e70063 DOI: 10.1002/imt2.70063

CORRESPONDENCE

Neoadjuvant immunotherapy driven bladder preservation for muscle invasive bladder cancer

Jiao Hu ¹^,²^,³
, Luzhe Yan ¹^,²^,³
, Jinhui Liu ¹^,²^,³
, Minfeng Chen ¹^,²^,³
, Yunbo He ¹^,²^,³
, Benyi Fan ¹^,²^,³
, Bo Peng ⁴
, Long Wang ⁵
, Weibin Hou ⁵
, Chao Li ⁵
, Bosen You ⁶
, Meng Zhang ⁷
, Wenze Li ³^,⁸
, Jiaxing Wang ⁸
, Hongzhou Cai ⁹
, Shenglin Gao ¹⁰
, Yang Liu ¹¹
, Dingshan Deng ¹^,²^,³
, Huihuang Li ¹^,²^,³
, Guanghui Gong ¹²
, Jiansheng Tang ¹³
, Chengyong Wang ¹⁴
, Xiaofeng Yang ¹⁵
, Liang Wei ¹⁵
, Guangzheng Lin ¹⁶
, Ruizhe Wang ¹^,²^,³
, Xiao Guan ¹^,²^,³
, Shiyu Tong ¹^,²^,³
, Yangle Li ¹^,²^,³
, Wei He ¹^,²^,³
, Zhiyong Cai ¹^,²^,³
, Peihua Liu ¹^,²^,³
, Yu Gan ¹^,²^,³
, Yu Cui ¹^,²^,³
, Yuanqing Dai ¹^,²^,³
, Yi Cai ¹^,²^,³
, Zefu Liu ¹^,²^,³
, Jiatong Xiao ¹^,²^,³
, Zhenyu Nie ¹^,²^,³
, Zhenyu Ou ¹^,²^,³
, Jinbo Chen ¹^,²^,³
, Xi Guo ¹⁷
, Xiongbing Zu ¹^,²^,³^,¹⁷

Author information +

¹. Department of Urology, Xiangya Hospital, Central South University, Changsha, China

². National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China

³. Furong Laboratory, Changsha, China

⁴. Department of Urology, Zhangjiajie People's Hospital, Zhangjiajie, China

⁵. Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, China

⁶. Department of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

⁷. Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China

⁸. Department of Urology, The First People's Hospital of Xiangtan City, Xiangtan, China

⁹. Department of Urology, Jiangsu Cancer Hospital & The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research, Nanjing Medical University, Nanjing, China

¹⁰. Department of Urology, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, China

¹¹. Department of Urology and Guangdong Key Lab of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

¹². Department of Pathology, Xiangya Hospital, Central South University, Changsha, China

¹³. Department of Urology, The Affiliated Hospital of Xiangnan University, Xiangnan University, Chenzhou, China

¹⁴. Department of Urology, The First Affiliated Hospital of Bengbu Medical College, Anhui, Bengbu, China

¹⁵. Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, China

¹⁶. Department of Urology, The Second Hospital of Anhui Medical University, Hefei, China

¹⁷. Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China

chenjinbo@csu.edu.cn

guoxiliu99@163.com

zuxbxy@csu.edu.cn

Show less

History +

PDF

Cite this article

Download citation ▾

Jiao Hu, Luzhe Yan, Jinhui Liu, Minfeng Chen, Yunbo He, Benyi Fan, Bo Peng, Long Wang, Weibin Hou, Chao Li, Bosen You, Meng Zhang, Wenze Li, Jiaxing Wang, Hongzhou Cai, Shenglin Gao, Yang Liu, Dingshan Deng, Huihuang Li, Guanghui Gong, Jiansheng Tang, Chengyong Wang, Xiaofeng Yang, Liang Wei, Guangzheng Lin, Ruizhe Wang, Xiao Guan, Shiyu Tong, Yangle Li, Wei He, Zhiyong Cai, Peihua Liu, Yu Gan, Yu Cui, Yuanqing Dai, Yi Cai, Zefu Liu, Jiatong Xiao, Zhenyu Nie, Zhenyu Ou, Jinbo Chen, Xi Guo, Xiongbing Zu. Neoadjuvant immunotherapy driven bladder preservation for muscle invasive bladder cancer. iMeta, 2025, 4(4): e70063 DOI:10.1002/imt2.70063

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Patel Vaibhav, G., K. Oh William, and D. Galsky Matthew. 2020. “Treatment of Muscle-Invasive and Advanced Bladder Cancer in 2020.” CA: A Cancer Journal for Clinicians 70: 404-423. https://doi.org/10.3322/caac.21631

[2]

Compérat, Eva, Mahul B. Amin, Richard Cathomas, Ananya Choudhury, Maria De Santis, Ashish Kamat, Arnulf Stenzl, Harriet C. Thoeny, and Johannes Alfred Witjes. 2022. “Current Best Practice for Bladder Cancer: A Narrative Review of Diagnostics and Treatments.” Lancet 400: 1712-1721. https://doi.org/10.1016/S0140-6736(22)01188-6

[3]	Chinese, Urological, and Oncology Group. 2024. “Expert Consensus of Multi-Disciplinary Collaboration on Bladder-Preserving Treatment for Bladder Cancer in China (2024 Edition).” Chinese Journal of Oncology 46: 1136-1155. https://doi.org/10.3760/cma.j.cn112152-20240602-00231

[4]

Szabados, Bernadett, Mark Kockx, Zoe June Assaf, Pieter-Jan Van Dam, Alejo Rodriguez-Vida, Ignacio Duran, Simon J. Crabb, et al. 2022. “Final Results of Neoadjuvant Atezolizumab in Cisplatin-Ineligible Patients With Muscle-Invasive Urothelial Cancer of the Bladder.” European Urology 82: 212-222. https://doi.org/10.1016/j.eururo.2022.04.013

[5]

Dracham, Chinna Babu, Narendra Kumar, Santosh Kumar, Arun Elangovan, Budhi Singh Yadav, Ravimohan S. Mavuduru, Anupam Lal, Pramod K. Gupta, and Rakesh Kapoor. 2022. “A Phase II Study of Neoadjuvant Chemotherapy Followed by Organ Preservation in Patients With Muscle-Invasive Bladder Cancer.” Asian Journal of Urology 9: 318-328. https://doi.org/10.1016/j.ajur.2021.06.006

[6]

Geynisman, Daniel M., Philip H. Abbosh, Eric Ross, Matthew R. Zibelman, Pooja Ghatalia, Fern Anari, James R. Mark, et al. 2025. “Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).” Journal of Clinical Oncology 43: 1113-1122. https://doi.org/10.1200/JCO-24-01214

[7]

Zeng, Yu, Changqi Li, Chengcheng Lv, Cheng Fu, Ang Chen, Shui Fu, Huan Bi, et al. 2024. “Bladder-Sparing Treatment for Muscle-Invasive Bladder Carcinoma: A Single-Center, Single-Arm Clinical Study of Sequential Neoadjuvant Chemotherapy Followed by Tislelizumab Neoadjuvant Immunotherapy.” Journal of Clinical Oncology 42(4_suppl): 596. https://doi.org/10.1200/JCO.2024.42.4_suppl.596

[8]

Galsky, Matt D., Siamak Daneshmand, Sara C. Lewis, Kevin G. Chan, Tanya B. Dorff, Jeremy Paul Cetnar, Ronac Mamtani, et al. 2023. “Co-Primary Endpoint Analysis of HCRN GU 16-257: Phase 2 Trial of Gemcitabine, Cisplatin, Plus Nivolumab With Selective Bladder Sparing in Patients With Muscle-Invasive Bladder Cancer (MIBC).” Journal of Clinical Oncology 41(6_suppl): 447. https://doi.org/10.1200/JCO.2023.41.6_suppl.447

[9]

Wen, Feng, Tianhai Lin, Ping Tan, Jiani Deng, Min Ren, Mengni Zhang, Xiaonan Zheng, Peng Zhang, and Yali Shen. 2025. “Long-Term Results of a Phase 2 Study of Neoadjuvant Chemotherapy Combined With Tislelizumab Followed by Radiotherapy for Bladder-Preserving Treatment in Selected High-Risk/Locally Advanced Muscle Invasive Urothelial Bladder Cancer (HOPE-02).” Journal of Clinical Oncology 43(5_suppl): 786. https://doi.org/10.1200/JCO.2025.43.5_suppl.786

[10]

Wen, Feng, Tianhai Lin, Ping Tan, Jiani Deng, Min Ren, Mengni Zhang, Xiaonan Zheng, Peng Zhang, and Yali Shen. 2025. “A Multi-Center Phase Ib/II Study of RC48-ADC Combined With Tislelizumab as Neoadjuvant Treatment in Patients With HER2 Positive Locally Advanced Muscle-Invasive Urothelial Bladder Cancer (Hope-03).” Journal of Clinical Oncology 43(5_suppl): 795. https://doi.org/10.1200/JCO.2025.43.5_suppl.795

[11]

Rouanne, Mathieu, Dean F. Bajorin, Raquibul Hannan, Matthew D. Galsky, Stephen B. Williams, Andrea Necchi, Padmanee Sharma, and Thomas Powles. 2020. “Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.” European Urology Oncology 3: 728-738. https://doi.org/10.1016/j.euo.2020.06.009

[12]	Abril-Rodriguez, Gabriel, and Antoni Ribas. 2017. “SnapShot: Immune Checkpoint Inhibitors.” Cancer Cell 31: 848-848.e1-e841. https://doi.org/10.1016/j.ccell.2017.05.010

[13]

Hu, Jiao, Jinbo Chen, Zhenyu Ou, Haige Chen, Zheng Liu, Minfeng Chen, Ruiyun Zhang, et al. 2022. “Neoadjuvant Immunotherapy, Chemotherapy, and Combination Therapy in Muscle-Invasive Bladder Cancer: A Multi-Center Real-World Retrospective Study.” Cell Reports Medicine 3: 100785. https://doi.org/10.1016/j.xcrm.2022.100785

[14]

Hu, Jiao, Luzhe Yan, Jinhui Liu, Minfeng Chen, Peihua Liu, Dingshan Deng, Chaobin Zhang, et al. 2025. “Efficacy and Biomarker Analysis of Neoadjuvant Disitamab Vedotin (RC48-ADC) Combined Immunotherapy in Patients With Muscle-Invasive Bladder Cancer: A Multi-Center Real-World Study.” iMeta 4: e70033. https://doi.org/10.1002/imt2.70033

[15]

Mitin, Timur, Asha George, Anthony L. Zietman, Niall M. Heney, Donald S. Kaufman, Robert G. Uzzo, Robert Dreicer, et al. 2016. “Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.” International Journal of Radiation Oncology, Biology, Physics 94: 67-74. https://doi.org/10.1016/j.ijrobp.2015.09.030

[16]

Hafeez, S., A. Horwich, O. Omar, K. Mohammed, A. Thompson, P. Kumar, V. Khoo, et al. 2015. “Selective Organ Preservation With Neo-Adjuvant Chemotherapy for the Treatment of Muscle Invasive Transitional Cell Carcinoma of the Bladder.” British Journal of Cancer 112: 1626-1635. https://doi.org/10.1038/bjc.2015.109